Detection of pyruvate metabolism disorders by culture of skin fibroblasts with dichloroacetate.
For use in screening for disorders of pyruvate metabolism, a sensitive assay method was developed for measuring the rate of decarboxylation of [1-14C]pyruvate during in vitro culture of skin fibroblasts with dichloroacetate (DCA). The rate of decarboxylation of [1-14C]pyruvate by skin fibroblasts from control subjects increased from 59.6 +/- 13.2 to 97.3 +/- 12.0 nmol/h/mg protein during in vitro culture in medium supplemented with 10 mM DCA for 3 days. In contrast, the rate hardly increased in cells from four of 20 patients with congenital lactic acidosis of unknown cause during in vitro culture with DCA. On day 3 of culture, the values for the four patients did not overlap those of control cells and so these four patients could be clearly distinguished from control subjects. Measurements of the original activity and the activity of the pyruvate dehydrogenase (PDH) complex after activation with a broad specificity protein phosphatase and DCA suggested that in three of the patients the aberration was a disorder in the mechanism for activation of PDH, including deficiency of PDH phosphatase or a mutation of PDH itself, whereas that in the fourth patient it might be a disorder of the mitochondrial transport system for pyruvate. Thus, measurement of the rate of decarboxylation of [1-14C]pyruvate by skin fibroblasts cultured in medium supplemented with 10 mM DCA for 3 days is a useful method for screening for disorders of pyruvate metabolism in cultured skin fibroblasts.
Naito
E
E
Department of Pediatrics, School of Medicine, University of Tokushima, Japan.
Kuroda
Y
Y
Takeda
E
E
Yokota
I
I
Kobashi
H
H
Miyao
M
M
D000085:Acetates / Q000378:metabolism; D000140:Acidosis, Lactic / Q000151:congenital / Q000175:diagnosis* / Q000473:pathology; D002478:Cells, Cultured; D002648:Child; D003999:Dichloroacetic Acid / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007223:Infant; D008297:Male; D008928:Mitochondria / Q000378:metabolism; D010749:Phosphoprotein Phosphatases / Q000494:pharmacology; D015325:Pyruvate Dehydrogenase Complex Deficiency Disease; D011773:Pyruvates / Q000378:metabolism*; D019289:Pyruvic Acid
D000085:Acetates; D011773:Pyruvates; D019289:Pyruvic Acid; D003999:Dichloroacetic Acid; D010749:Phosphoprotein Phosphatases